People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)

This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

38

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35222
    • California
      • Los Angeles, California, United States, 90035
        • University of California, Los Angeles CARE Center (Site ID: 601)
        • Contact:
      • San Diego, California, United States, 92103
        • UCSD Antiviral Research Center (Site ID: 701)
        • Contact:
      • San Francisco, California, United States, 94110
        • University of California, San Francisco (Site ID: 801)
        • Contact:
      • Torrance, California, United States, 90502-2052
        • Harbor University of California Los Angeles Center (Site ID: 603)
        • Contact:
    • Colorado
      • Aurora, Colorado, United States, 80045
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20032
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Northwestern University (Site ID: 2701)
        • Contact:
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Johns Hopkins University (Site ID: 201)
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital (Site ID: 101)
        • Contact:
      • Boston, Massachusetts, United States, 02115
        • Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
        • Contact:
    • New Jersey
      • Newark, New Jersey, United States, 07103
        • New Jersey Medical School Clinical Research Center (Site ID: 31786)
        • Contact:
    • New York
      • New York, New York, United States, 10010
        • Weill Cornell Chelsea (Site ID: 7804)
        • Contact:
      • New York, New York, United States, 10010
        • Weill Cornell Uptown (Site ID: 7803)
        • Contact:
      • New York, New York, United States, 10032
        • Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
        • Contact:
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599-7215
        • Chapel Hill (Site ID: 3201)
        • Contact:
      • Greensboro, North Carolina, United States, 27401-1020
    • Ohio
      • Cincinnati, Ohio, United States, 45267-0405
        • Cincinnati Clinical Research Site (Site ID: 2401)
        • Contact:
      • Cleveland, Ohio, United States, 44106
      • Columbus, Ohio, United States, 43210
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • University of Pittsburgh (Site ID: 1001)
        • Contact:
    • Tennessee
      • Nashville, Tennessee, United States, 37204
    • Texas
      • Houston, Texas, United States, 77030
        • Houston Advancing Research Team (Site ID: 31473)
        • Contact:
    • Washington
      • Seattle, Washington, United States, 98104
        • University of Washington Positive Research (Site ID: 1401)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Documented HIV-1 infection

  • Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use

  • HIV-1 RNA >1000 copies/mL within 60 days prior to study entry

  • Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence

  • At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance

  • Adequate laboratory parameters within 60 days prior to study entry:

    • Absolute neutrophil count >600/mm3
    • Hemoglobin ≥7.0 g/dL
    • Platelet count >50,000/μL
    • AST and ALT ≤3 × upper limit of normal
    • Estimated glomerular filtration rate >15 mL/min/1.73 m²
  • For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry

  • Ability and willingness to provide informed consent

  • Connected to a medical clinic with access to HIV care and antiretroviral therapy

Exclusion Criteria:

  • Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
  • Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
  • Child-Pugh Class C cirrhosis
  • No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
  • Prior use of lenacapavir
  • Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
  • Serious medical or psychiatric condition
  • Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
  • Current pregnancy or breastfeeding
  • Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir

Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation.

Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses.

Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Time Frame: Baseline through Week 48
Baseline through Week 48

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Time Frame: Week 48
Week 48
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Time Frame: Week 48
Week 48
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Time Frame: Week 48
Week 48
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Time Frame: Baseline through Week 96
Baseline through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Time Frame: Baseline through Week 96
Baseline through Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Time Frame: Baseline through Week 96
Baseline through Week 96
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Time Frame: Week 96
Week 96
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Time Frame: Week 96
Week 96
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Time Frame: Week 96
Week 96
Percentage of on-time long-acting injections
Time Frame: Through Week 48 and through Week 96
Through Week 48 and through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Time Frame: Baseline through Week 48 and through Week 96
Baseline through Week 48 and through Week 96
Plasma trough concentrations of lenacapavir and cabotegravir
Time Frame: Through Week 48 and through Week 96
Through Week 48 and through Week 96
Change in CD4 cell count from baseline
Time Frame: Week 48 and Week 96
Week 48 and Week 96
Participant-reported treatment satisfaction
Time Frame: Week 48 and Week 96

HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment.

Week 48 and Week 96
Change in quality-of-life scores from baseline
Time Frame: Week 48 and Week 96

Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

Week 48 and Week 96
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Time Frame: Week 48 and Week 96

Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

Week 48 and Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Time Frame: Baseline through Week 48
Baseline through Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Time Frame: Week 48
Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Time Frame: Week 48
Week 48
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Time Frame: Week 48
Week 48

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2028

Primary Completion (Estimated)

August 31, 2029

Study Completion (Estimated)

October 26, 2030

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • A5431
  • 39159 (Other Identifier: DAIDS-ES ID)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data that underlie results in the publication after deidentification

IPD Sharing Time Frame

Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

IPD Sharing Access Criteria

With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.

For what types of analyses? To achieve aims in the proposal approved by the ACTG.

By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe